Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.43 |
| ▸ | ITGAV | P06756 | 7/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.36 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | TPH1 | P17752 | 1/20 | 0.35 |
| ▸ | TPH2 | Q8IWU9 | 1/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8043850 | 1.00 | ITGB3 (0.43) | ITGB3ITGAVSYKMAOAITGA2B | |
| SCHEMBL8032379 | 0.92 | ITGB3 (0.46) | ITGB3ITGAVITGA2BITGA4ITGB7 | |
| SCHEMBL30963677 | 0.85 | ITGB3 (0.47) | ITGB3ITGAVITGA2B | |
| SCHEMBL8050913 | 0.85 | ITGB3 (0.47) | ITGB3ITGAVITGA2B | |
| SCHEMBL8047151 | 0.73 | ITGB3 (0.59) | ITGB3ITGAV | |
| SCHEMBL8250283 | 0.72 | ITGB3 (0.51) | ITGB3ITGAV | |
| SCHEMBL3897638 | 0.69 | SYK (0.72) | SYK | |
| SCHEMBL5176163 | 0.68 | SYK (0.49) | SYK | |
| SCHEMBL15372523 | 0.67 | ITGB3 (0.40) | ITGB3ITGAVSYKMAOAITGA2B | |
| SCHEMBL6481226 | 0.67 | ITGB3 (0.41) | ITGB3ITGAVSYKMAOAITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051423-A1 | NITROGEN HETEROCYCLE BIARYLS FOR OSTEOPOROSIS AND OTHER DISEASES | PHARMACOPEIA, INC. (US) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051423-A1 | NITROGEN HETEROCYCLE BIARYLS FOR OSTEOPOROSIS AND OTHER DISEASES | EDNRA, EDNRB, ESRRB | ITGB3 672/4885ITGAV 1292/4885SYK 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.